Status:
UNKNOWN
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Lead Sponsor:
Sheba Medical Center
Conditions:
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patient...
Eligibility Criteria
Inclusion
- Participants eligible for inclusion will include non-pregnant adult (\>18 years old) with molecular confirmation of COVID-19. \[Participants will be eligible in a period of no longer than 72 hours after exposure\].
Exclusion
- Severe infection ( defined as need for invasive or non-invasive ventilator support, ECMO or shock requiring vasopressor support).
- Weight below 40Kg or above 100Kg
- Unable to take oral medication
- Known allergy to the drugs
- Pregnancy or breast feeding
- Participating in another RCT for treatment of COVID-19.
Key Trial Info
Start Date :
May 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04429711
Start Date
May 12 2020
End Date
October 31 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel